Demographic and clinical characteristics of NSCLC patients
| Demographic and clinical data | Number and percentage (%) |
|---|---|
| Total of patients | 18 (100%) |
| Sex | |
| Male | 12 (66.7%) |
| Female | 6 (33.3%) |
| Histologic subtype | |
| Adenocarcinoma | 11 (61.1%) |
| Squamous cell carcinoma | 4 (22.2%) |
| NSCLC | 3 (16.7%) |
| ECOG status | |
| ECOG status 0 | 5 (27.8%) |
| ECOG status 1 | 11 (61.1%) |
| ECOG status 2 | 2 (11.1%) |
| Response to first-line treatment | |
| Complete response | 2 (11.1%) |
| Partial response | 4 (22.2%) |
| Stable disease | 11 (61.1%) |
| Progressive disease | 1 (5.6%) |
The proportion of patients in each category indicated was calculated from the total absolute number of patients in this study. ECOG: Eastern Cooperative Oncology Group; NSCLC: non-small cell lung cancer
Note. Adapted from “Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy” by Suárez GM, Catalá M, Peña Y, Portela S, Añé-Kourí AL, González A, et al. Front Oncol. 2022;12:823287 (https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.823287/full). CC BY.